NKTR

SEC source: 0001209191-18-018223 · doc4.xml · nonDerivative · entry 2

KUEBLER CHRISTOPHER A · CIK 0001229877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,500

F1 · price: This transaction was executed in multiple trades at prices ranging from $100.00 to $101.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-018223 · doc4.xml · nonDerivative · entry 1

KUEBLER CHRISTOPHER A · CIK 0001229877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-018221 · doc4.xml · nonDerivative · entry 1

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,657

F1 · price: This transaction was executed in multiple trades at prices ranging from $98.00 to $100.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-011598 · doc4.xml · nonDerivative · entry 1

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,857

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,703 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-18-011597 · doc4.xml · nonDerivative · entry 1

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,147

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-011595 · doc4.xml · nonDerivative · entry 1

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,657

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-011590 · doc4.xml · nonDerivative · entry 1

Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,261

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 6,500 shares held by the reporting person from the Issuer's ESPP Plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c).

SEC source: 0001209191-18-011592 · doc4.xml · nonDerivative · entry 1

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,739

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-18-011587 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,394

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-007139 · doc4.xml · derivative · entry 2

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 120,000 shares

Expires 2018-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made for stock options scheduled to expire on February 1, 2018.

SEC source: 0001209191-18-007139 · doc4.xml · nonDerivative · entry 1

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made for stock options scheduled to expire on February 1, 2018.

SEC source: 0001209191-18-005221 · doc4.xml · derivative · entry 4

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,333 shares

Expires 2018-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

SEC source: 0001209191-18-005221 · doc4.xml · nonDerivative · entry 2

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,935

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $72.39 to $79.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-005221 · doc4.xml · nonDerivative · entry 1

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

SEC source: 0001209191-18-002773 · doc4.xml · derivative · entry 4

WINGER DENNIS L · CIK 0001222645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2018-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018.

SEC source: 0001209191-18-002773 · doc4.xml · derivative · entry 3

WINGER DENNIS L · CIK 0001222645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires 2018-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018.

SEC source: 0001209191-18-002773 · doc4.xml · nonDerivative · entry 1

WINGER DENNIS L · CIK 0001222645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018.

SEC source: 0001209191-18-002177 · doc4.xml · derivative · entry 3

KUEBLER CHRISTOPHER A · CIK 0001229877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2018-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for stock options expiring in 2018.

SEC source: 0001209191-18-002177 · doc4.xml · nonDerivative · entry 2

KUEBLER CHRISTOPHER A · CIK 0001229877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,500

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for stock options expiring in 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $57.81 to $59.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-002177 · doc4.xml · nonDerivative · entry 1

KUEBLER CHRISTOPHER A · CIK 0001229877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for stock options expiring in 2018.

SEC source: 0001209191-17-066483 · doc4.xml · derivative · entry 2

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2025-12-14

F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066483 · doc4.xml · nonDerivative · entry 1

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,402

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,703 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-066485 · doc4.xml · derivative · entry 3

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,250

Underlying: Common Stock · 151,250 shares

Expires 2025-12-14

F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066485 · doc4.xml · nonDerivative · entry 1

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,935

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

SEC source: 0001209191-17-066481 · doc4.xml · derivative · entry 2

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2025-12-14

F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066481 · doc4.xml · nonDerivative · entry 1

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,536

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

SEC source: 0001209191-17-066479 · doc4.xml · derivative · entry 2

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2025-12-14

F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066479 · doc4.xml · nonDerivative · entry 1

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,216

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-066478 · doc4.xml · derivative · entry 2

Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2025-12-14

F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066478 · doc4.xml · nonDerivative · entry 1

Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,136

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

F2 · balance_after: This number includes 6,500 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-066475 · doc4.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2025-12-14

F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066475 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,820

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

SEC source: 0001209191-17-066050 · doc4.xml · derivative · entry 4

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,333

Underlying: Common Stock · 83,333 shares

Expires 2018-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

SEC source: 0001209191-17-066050 · doc4.xml · nonDerivative · entry 2

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,435

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $54.26 to $56.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-066050 · doc4.xml · nonDerivative · entry 1

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,768

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

SEC source: 0001209191-17-061597 · doc4.xml · nonDerivative · entry 2

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,549

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-061596 · doc4.xml · nonDerivative · entry 2

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,435

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-061594 · doc4.xml · nonDerivative · entry 2

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,536

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-061592 · doc4.xml · nonDerivative · entry 2

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,716

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-061591 · doc4.xml · nonDerivative · entry 2

Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,636

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3 · balance_after: This number includes 6,000 shares held by the reporting person from the Issuer's ESPP Plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-061590 · doc4.xml · nonDerivative · entry 2

Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,553

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-061588 · doc4.xml · nonDerivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,820

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-061597 · doc4.xml · derivative · entry 3

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2024-12-12

F6 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F7 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F8 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

SEC source: 0001209191-17-061597 · doc4.xml · nonDerivative · entry 1

Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,838

F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).

F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

SEC source: 0001209191-17-061596 · doc4.xml · derivative · entry 4

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,500

Underlying: Common Stock · 137,500 shares

Expires 2024-12-12

F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

SEC source: 0001209191-17-061596 · doc4.xml · nonDerivative · entry 1

ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,504

F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).

SEC source: 0001209191-17-061594 · doc4.xml · derivative · entry 3

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2024-12-12

F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

SEC source: 0001209191-17-061594 · doc4.xml · nonDerivative · entry 1

Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,156

F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).

SEC source: 0001209191-17-061592 · doc4.xml · derivative · entry 3

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2024-12-12

F6 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F7 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F8 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

SEC source: 0001209191-17-061592 · doc4.xml · nonDerivative · entry 1

Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,414

F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).

F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).